• PET scanners
• Linear accelerators
• Lithiotripter machines
• Gamma cameras
  

According to GHI analysis, only 5% of the hospitals in the region possess these equipment types.

But beyond identifying this 5%, the webinar — entitled The Adoption and Penetration of High-Tech Equipment in Latin America — exhaustively examined the factors that lead hospitals to acquire high-tech equipment.

Most importantly, the webinar features GHI’s TechTier Adoption Model. Based on statistical analysis of hospital ownership and acquisition of more than 40 types of equipment, ranging from basic (such as infusion pumps or newborn cribs) to cutting-edge, expensive equipment and devices, TechTier reveals the stages that hospitals go through as they advance from providing basic, essential care to higher degrees of specialization and more innovative treatments for medical conditions. For medical equipment manufacturers, the TechTier model and a new service developed by GHI can make the difference between increasing your sales success with high-level equipment — or still struggling to find clients and close.

Step Up Your Sales  

Contact GHI today to see how this statistical modeling and data-driven approach can deliver you a fresh new batch of sales targets for your high-tech equipment that may well surprise you. While your sales team may have great experience and contact, our analysis of data that comes straight from the hospitals themselves may help you expand your CRM (and sales pipeline) to a new level.

To explore more of what GHI shared in the webinar, please click here to download the presentation slides and scroll down to view the webinar recording in its entirety.

In the Federal District, 1,068 people must undergo hemodialysis and 281 need peritoneal dialysis. The main causes for kidney disease in the country are diabetes and high blood pressure. The symptoms such as anemia, high blood pressure, swelling (edema), and tiredness go unnoticed. It is only the most advanced stage of the disease that patients are referred the renal replacement therapy. According to SBN, three types of treatment can be chosen: hemodialysis, peritoneal dialysis (performed at home) or kidney transplantation. People see dialysis as negative, and hence do not prefer it. As per the SBN, Brazil has 747 hemodialysis clinics, indicating 164 patients per clinic. The data indicates that the number of clinics is not meeting the demand, and the last resort for patients is home dialysis. In the Federal District, seven public hospitals treat patients with renal failure: Asa Norte, Sobradinho, Santa Maria, Gama, Taguatinga and Ceilândia; Base Hospital and University Hospital of Brasília.

To ease home treatments for patients, the company Baxter launched “HomeChoice Claria” in Brazil. The equipment allows physicians to remotely monitor and analyze patients undergoing peritoneal dialysis. The system works via a cloud data storage system, which facilitates the visualization of information related to the dialysis of each patient. Based on the information doctors can remotely and safely adjust the settings of each person’s home devices without having the need to move patients to clinics or hospitals. In Latin America, 2,234 patients already use the new equipment, it has shown significant improvements in treatment along with increased adherence to treatment.

Noticias

The self- tests were first launched Rio de Janeiro, followed by Sao Paulo and Espírito Santo. By the end of the month they are expected to reach the whole territory. The “self-test”, approved by the National Agency of Sanitary Surveillance (Anvisa), allows the user to know if he is carrying the AIDS virus, which is very useful in a country of more than 200 million inhabitants where the people are often reluctant to go to diagnostic centers.

According to data from the Fiocruz public medical research foundation, approximately 20% of the 800,000 HIV-positive people in Mexico are unaware that they are HIV-positive. The sooner the virus is detected, the better it is treated. The problem is that many Brazilians do not get tested in the hospital, out of shame or fear of being victims of discrimination.

The “self-tests” are already commercialized in countries like United States, United Kingdom and France. Brazil offers free treatment to anyone diagnosed as HIV positive. The test was developed by a local company OrangeLife. The test works by collecting a drop of blood mixed with a reactive product to detect antibodies that signal exposure to HIV. With a price between 60-70 reais (USD18-21 dollars), the result is known in 20 minutes.

The manufacturers claim the test is 99.9% accurate and reliable, a rate that surpasses the detection capability of tests that use saliva and are marketed in the United States. According to the company OrangeLife, the tests are produced in a factory in Rio with a capacity to prepare 100,000 units per month. For all the stakeholders including pharmaceuticals, doctors, and the manufacturer, this test represents an important advance in the fight against HIV.

The Ministry of Health had announced its intention to limit the number of Cubans travelling in this program. The reduction of the participation of foreign professionals, however, should be done gradually.

Medical care should not be disturbed especially in the regions where there is gap in permanent Brazilian doctors. The professionals arrive in Brazil through an agreement signed with the Pan American Health Organization (PAHO) and the Cuban government. However, plans are to gradually reduce the number to 4,000 Cubans and replace them with Brazilian medical professionals.

In 2016, 10,400 Cubans were working in the program, a 1,000 less from 2015. The agreement signed between the Brazilian and Cuban government and the PAHO provided that professionals recruited on the program would stay in the country for three years.

Although the law allowed the group to spend three more years in Brazil, new agreement signed in September 2016 states that professionals recruited in the first cycle (~4,000) should return to the country for circulation of new set of professionals. Permission to extend the term for these professionals for another three years would be granted in case of established families in Brazil.

According to official data around 12,000 people from Venezuela have entered the country since 2014. Hospitals in Roraima indicate that majority of the patients are Venezuelans. This is burdening the medical supplies of the region leading to critically low stock. According to Brazilian health professionals, Venezuelans usually arrive at hospitals in severe conditions requiring immediate medical attention.

Increase in incidence of diseases like HIV, tuberculosis and malaria has been observed. The hospitalization rate of Brazilians in the general hospital is 7% while that of Venezuelans reaches to 20%. Other countries in the region have also registered a significant increase in immigrants from Venezuela.

In addition, a significant increase in the number of asylum requests for Venezuelans has increased in the country reaching 2,595 in the first 11 months of 2016, against 54 in 2013. Despite the shortage of medicines and food in the Venezuela, bureaucratic obstacles hinder import of products.

It is of opinion that Brazil and other countries must press for Venezuela to accept international aid to minimize the impact of economic problems and the political crisis on the population.

The aim of the plan is to reduce the incidence to 10 per 100,000 cases by 2035. This plan reaffirms the country’s commitment to the World Health Organization (WHO) and marks the World Tuberculosis Day, celebrated on 24^th March. The plan defines the indicators to be monitored by states and municipalities in the health care network.

The objective of the plan is early diagnosis, continuous treatment and reducing abandonment before the recommended period. The national plan is divided into three pillars. First is integrated and patient-centered prevention and care, second is strong public policies and support system and third is strengthening of research and innovation.

Disease control will be made based on indicators such as detection, diagnosis, TB-HIV co-infection, completion of treatment and cases of latent, sensitive and drug-resistant tuberculosis. To raise public awareness about tuberculosis, the MoH is running campaigns.

The campaign emphasizes that responsibility for treatment should be shared by patient, health care team, family, and friends. In addition to people with HIV, lower income population who have difficulty in accessing health services are prone to tuberculosis.

According to the MoH, 9.7% of confirmed tuberculosis cases had HIV in 2015. In 2016, 66,700 new cases and 12,800 relapse cases were registered in Brazil. The mortality coefficient for tuberculosis reduced by 15.4%, from 2.6 per 100,000 inhabitants in 2006 to 2.2 per 100,000 in 2015. Brazil registered 4,500 deaths from tuberculosis in 2015. Incidence in Rio de Janeiro is 5 per 100,000 people and Pará is 2.6 per 100,000 people.

According to the WHO, tuberculosis was the leading cause of mortality globally in 2015 and may have killed more than 1.8 million people. Six countries accounted for 60% of all new cases in 2015 namely India, Indonesia, China, Nigeria, Pakistan and South Africa. In 2014, the Ministry of Health Rapid Test Network for Tuberculosis (RTR-TB), a diagnostic test which detects the presence of the bacillus causing the disease in two hours and identifies rifampicin resistance. For 2017, the MoH has planned to distribute 70 new equipments with the capacity to do 250,000 tests.

• Number of hospitals: 7,878
• Number of hospital beds per hospital (average): 24
• Operating rooms per hospital (average): 2.0

Penetration of:

• Ventilators: 610%
• Infusion pumps: 2041%
• MRI: 7%
• PET: <1%
• Ultrasound: 124%

Download the complete report for more information or explore our Latin American hospitals database, the world’s largest, covering 86% of the hospitals in Latin America with 130+ data points per hospital.

[thrive_leads id=’7635′]

Brazil also ranks alongside Ukraine, Australia and the US, as one of the nations with the highest population depression rate (5.9% out of total, or about 11.5 million people) globally. Some data, taken from the Center for Valuing Life (CVV), a Brazilian non-profit organization that provides people having suicidal tendencies with telephone assistance, expose that one case occurs every 43 minutes. The WHO warned that around 800 thousand people annually die due to theses tendencies, considered as the second cause of death in the Brazilian population between 15-29 years. People suffering from depression are lacking medical care and in many other countries less than 10% of depressed patients access medical care.

Latin America home healthcare market, by geography is segmented as Brazil, Mexico, Colombia, Argentina and others. Brazil contributed for the largest share, i.e. around 35%, in 2013 of the Latin America home healthcare market. Increasing healthcare awareness and rising healthcare expenditure on chronic diseases in Brazil drive the market of home healthcare in Brazil. Mexico contributed the second largest share i.e. over 25% of the total market in 2013 and is expected to witness fastest growth during the study period. High prevalence of diabetes and cardiovascular diseases and increasing healthcare investment by the Government of Mexico will support the growth of home healthcare in Mexico. The growth of home healthcare market in Argentina and Colombia is mainly attributed to the introduction of new technologies coupled with new product launch by key companies. Some of the prominent players in the Latin America home healthcare market are Omron Healthcare, Phillips Healthcare, Medtronic, F. Hoffmann-La Roche, Praxair Technologies, Teleflex Corporation, Bayer Healthcare, ResMed, GE Healthcare, Cardinal Health, Gentiva Health Services, Invacare Corporation, Johnson & Johnson, Abbott Laboratories and others.